Novasep has announced that it has been selected by Tetraphase for the commercial manufacture of the active pharmaceutical ingredient (API) eravacycline, an antibiotic being developed for the treatment of life-threatening infections, including those caused by multidrug-resistant, Gram-negative bacteria.

This manufacturing agreement with Tetraphase is the result of a successful collaboration that started in 2014 with the clinical supply of eravacycline. 

Dr Michel Spagnol, chairman and chief executive officer of Novasep, said, “Tetraphase has developed a robust and innovative chemistry process for their lead candidate, eravacycline. We are extremely grateful for the opportunity to continue working with Tetraphase; this new strategic manufacturing agreement will further strengthen our relationship.”

Eravacycline is a novel, fully-synthetic tetracycline antibiotic in a Phase 3 program for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. The FDA has granted Qualified Infectious Disease Product and Fast Track designations for eravacycline for both indications.